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ABSTRACT
Background: Evidence for the association between underlying non-alcoholic fatty liver 
disease (NAFLD), the risk of testing severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) positive, and the clinical consequences of coronavirus disease 2019 (COVID-19) is 
controversial and scarce. We aimed to investigate the association between the presence of 
NAFLD and the risk of SARS-CoV-2 infectivity and COVID-19-related outcomes.
Methods: We used the population-based, nationwide cohort in South Korea linked with 
the general health examination records between January 1, 2018 and July 30, 2020. Data for 
212,768 adults older than 20 years who underwent SARS-CoV-2 testing from January 1 to 
May 30, 2020, were obtained. The presence of NAFLDs was defined using three definitions, 
namely hepatic steatosis index (HSI), fatty liver index (FLI), and claims-based definition. The 
outcomes were SARS-CoV-2 test positive, COVID-19 severe illness, and related death.
Results: Among 74,244 adults who completed the general health examination, there were 
2,251 (3.0%) who were SARS-CoV-2 positive, 438 (0.6%) with severe COVID-19 illness, and 45 
(0.06%) COVID-19-related deaths. After exposure-driven propensity score matching, patients 
with pre-existing HSI-NAFLD, FLI-NAFLD, or claims-based NAFLD had an 11–23% increased 
risk of SARS-CoV-2 infection (HSI-NAFLD 95% confidence interval [CI], 1–28%; FLI-NAFLD 
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95% CI, 2–27%; and claims-based NAFLD 95% CI, 2–31%) and a 35–41% increased risk 
of severe COVID-19 illness (HSI-NAFLD 95% CI, 8–83%; FLI-NAFLD 95% CI, 5–71%; and 
claims-based NAFLD 95% CI, 1–92%). These associations are more evident as liver fibrosis 
advanced (based on the BARD scoring system). Similar patterns were observed in several 
sensitivity analyses including the full-unmatched cohort.
Conclusion: Patients with pre-existing NAFLDs have a higher likelihood of testing SARS-
CoV-2 positive and severe COVID-19 illness; this association was more evident in patients 
with NAFLD with advanced fibrosis. Our results suggest that extra attention should be given 
to the management of patients with NAFLD during the COVID-19 pandemic.
Keywords: COVID-19; SARS-CoV-2; Non-alcoholic Fatty Liver Disease; Hepatic Steatosis Index; 
Fatty Liver Index; BARD Scoring System
INTRODUCTION
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2), has rapidly spread worldwide.1,2 It is vital for 
clinicians to figure out how pre-existing comorbidities affect the infectivity risk and 
outcomes for this new, rapidly disseminating disease. Previous studies between liver disease 
and COVID-19 focused on hepatic manifestations of COVID-19 (such as elevated liver enzyme 
and COVID-19 induced hepatitis3) and pre-existing hepatic comorbidities including liver 
cirrhosis,4 liver-transplant recipient,5 and chronic liver disease.6 However, studies involving 
non-alcoholic fatty liver disease (NAFLD) have not evaluated the severity of COVID-19 
completely; there is also no study focusing on the association between SARS-CoV-2 
susceptibility and pre-existing NAFLD.5
NAFLD has a high prevalence and is the most common cause of chronic liver injury, but it has 
been underestimated over the past decades.7,8 As NAFLD is a metabolic disease that is not 
confined to the liver, it is associated with extra-hepatic manifestations, liver-related events, 
and mortality.7 Among patients with COVID-19, common findings include a 14–53% increase 
in liver enzyme levels,5 and the most common post-mortem histopathologic findings of the 
liver showed moderate macrovesicular steatosis and mild lobular inflammation.9 We believe 
that underlying NAFLD, which is characterized by predominant macrovesicular steatosis of 
the liver parenchyma, could be vulnerable to the attack of SARS-CoV-2.10
Thus, we hypothesized that the presence of NAFLD can influence the epidemiological aspects 
related to COVID-19, including infectivity and disease-related outcomes. For this reason, we 
aim to investigate the potential associations on COVID-19 infectivity, severity, and related 
death among NAFLD patients who underwent laboratory SARS-CoV-2 testing through a 
population-based, nationwide cohort in South Korea.
METHODS
Database
We conducted a population-based cohort study using data from the Korean National Health 
Insurance Service (KNHIS), which is linked to national COVID-19-related registers from the 
Korea Disease Control and Prevention Agency (KDCA). It provided the data of individuals who 
2/14https://jkms.org https://doi.org/10.3346/jkms.2021.36.e291
Non-alcoholic Fatty Liver Disease and COVID-19
underwent SARS-CoV-2 testing in South Korea between January 1 and May 30, 2020 by medical 
or KDCA referral (excluding self-referral). The KNHIS covers almost 98% of the total Korean 
population,11-13 and the Korean government provided mandatory and complementary health 
insurance for all COVID-19 patients during the pandemic.14 Data from the KNHIS included 
demographic characteristics, general health screening records, and medical history of inpatients 
and outpatients; on the other hand, COVID-19-related outcomes and death were taken from the 
KDCA data. This nationwide cohort dataset is anonymized using patient identifiers.
Study population
The preliminary results of our research have been published previously.15 All Korean individuals 
≥ 20 years of age who underwent SARS-CoV-2 testing between January 1, 2020 and May 30, 
2020 by medical or KDCA referral (excluding self-referral; n = 212,768) were enrolled. Among 
the 212,768 included subjects, subjects who did not recently receive general health examination 
(n = 136,373), those with another etiology of chronic liver disease (n = 1,818), and those with 
alcohol abuse/misuse (those with alcohol-related disease [F10.0, F10.1, F10.3, F10.4, F10.5, 
F10.6, F10.7, F10.8, F10.9, G62.1, K70.x, K70.0, K70.1, K70.2, K70.3, K70.4, K70.9, K86.0] and 
those who had alcohol intake more than 210 g [for men] and 140 g [for women] per week; n = 
638) were excluded from the study. After exclusion, 74,244 subjects were available for analysis. 
A positive SARS-CoV-2 test was confirmed by real-time reverse transcriptase-polymerase chain 
reaction assay of the specimen from nasal and pharyngeal swabs, which was authorized by the 
KDCA.16 The observational period was from January 1, 2020 to July 30, 2020, and individual 
index data was the data of the first SARS-CoV-2 testing for each patient.
Insurance eligibility data offered the baseline personal data such as age, gender, household 
income, and region of residence.11,17,18 The history of diagnosed comorbidities such as 
diabetes mellitus, tuberculosis, stroke, cardiovascular disease, hypertension, dyslipidemia, 
and current medication history for those diseases were also available from the general health 
examination that had been obtained through a personal medical interview. Lifestyle habits, 
such as smoking, alcohol consumption, and physical activity level, were also accessible 
from the general health examination.11 The body mass index (BMI), waist circumference 
(WC), and systolic/diastolic blood pressure were taken for all the patients. Laboratory data, 
including blood glucose, creatinine (used for glomerular filtration rate [GFR] calculation), 
aspartate transaminase (AST), alanine transaminase (ALT), triglyceride and gamma-glutamyl 
transferase (GGT), were obtained from a serum sample in the fasting state during general 
health examination.11
NAFLD definition (exposure)
Patients were divided according to the three types of NAFLD definition. Pre-existing NAFLD 
was regarded when one of the following criteria was satisfied: 1) hepatic steatosis index (HSI) 
≥ 36, 2) fatty liver index (FLI) ≥ 60, or 3) claim-based definition indicated by the International 
Classification of Diseases, 10th revision (ICD-10) (K75.8 and K76.0), with at least one claim 
within the observation period.19 HSI was calculated based on AST, ALT, BMI, female sex, 
and diabetes mellitus using the following formula20: HSI = 8 × ALT/AST ratio + BMI (+2, if 
diabetes mellitus; +2, if female). FLI was calculated based on BMI, WC, GGT, and triglyceride 
level by the following formula20:
3/14https://jkms.org https://doi.org/10.3346/jkms.2021.36.e291
Non-alcoholic Fatty Liver Disease and COVID-19
𝐹𝐹𝐹𝐹𝐹𝐹 =  [𝑒𝑒
0.953 × loge (TG/0.0113) + 0.139 × BMI + 0.718 × loge (GGT) + 0.053 × WC − 15.745]
[1 + 𝑒𝑒0.953 × loge (TG/0.0113) + 0.139 × BMI + 0.718 × loge (GGT) + 0.053 × WC − 15.745]  ×  100 
We calculated the BARD score to estimate the degree of fibrosis of NAFLD patients. The 
BARD score was calculated using BMI, AST, ALT, and presence of diabetes mellitus; NAFLD 
patients were categorized as those without advanced fibrosis (0–1) or those with advanced 
fibrosis (2–4).21
We generated three cohorts using these definitions to support the robustness and 
generalization of our results: 1) adaptation of HSI for NAFLD definition (HSI-NAFLD cohort), 
2) adaptation of FLI for NAFLD definition (FLI-NAFLD cohort), and 3) adaptation of claim-
based NAFLD definition (claim-based NAFLD cohort).
Outcomes
The study subjects were linked to the national COVID-19-related registers from the KDCA. 
The main outcomes were the positive laboratory SARS-CoV-2 tests, severe clinical COVID-19 
illnesses (requirement of oxygen therapy, administration of mechanical ventilation, 
international care unit admission, COVID-19-related death),16,22 and COVID-19-related deaths.
Statistical analysis
In this nationwide cohort, pre-existing NAFLD was defined as the “exposure” and positive 
SARS-CoV-2 tests or COVID-19-related outcomes were defined as the “outcomes”. We 
generated three exposure-driven propensity score matched cohorts to provide the robustness 
and generalization of our results. First, we performed 1:1 ratio of the exposure-driven 
propensity score matching using a “greedy nearest-neighbor” algorithm to balance the 
baseline and demographic covariates of the two groups and to reduce potential confounders 
from the predicted probability of 1) patients with HSI-NAFLD vs. those without HSI-NAFLD 
(HSI-NAFLD cohort), 2) patients with FLI-NAFLD vs. those without FLI-NAFLD (FLI-NAFLD 
cohort), and 3) patients with claim-based NAFLD vs. those without claim-based NAFLD 
(claim-based NAFLD cohort). We selected the following matching covariates: age (20–39, 
40–59, and ≥ 60 years), sex, region of residence (Seoul Capital Area, Daegu/Gyeongbuk area, 
and other areas), past medical history/comorbidities (tuberculosis, stroke, cardiovascular 
disease, hypertension, and dyslipidemia), systolic and diastolic blood pressure, fasting 
blood glucose, GFR (≥ 90, 60–89, ≤ 59 mL/min), household income (low, middle, and high), 
smoking (never, ex-, and current), alcoholic drinks (< 1, 1–2, 3–4, ≥ 5 days per week), sufficient 
aerobic activity (more than 500 metabolic equivalent task min/week), and current medication 
for hypertension, dyslipidemia, diabetes mellitus, and cardiovascular disease. We excluded 
the adjusted variables used in HSI, FLI, and BARD score (history of diabetes mellitus, WC, 
BMI, serum triglyceride, GGT, AST, and ALT) to avoid over-adjustment.
Subsequently, we used Firth logistic regressions to reduce the small sample bias, presented 
by adjusted odds ratios (aORs) with 95% confidence intervals (CIs) after adjusting for the 
potential confounders. We performed the main analyses from 1) HIS-NAFLD matched 
cohort (n = 34,842); 2) FLI-NAFLD matched cohort (n = 39,450); and 3) claims-based 
NAFLD matched cohort (n = 17,660). To investigate the severity-dependent relationship, we 
performed further analyses from the fully unmatched cohort, which were re-categorized as 
severity according to the BARD score (none vs. NAFLD without advanced fibrosis vs. NAFLD 
with advanced fibrosis).
Standardized mean differences (SMDs), score densities, and score distributions were used 
for determining adequacy of propensity score matching. An SMD of less than 0.1 was 
considered to have no major imbalance between matched pairs; a two-sided P value of less 
4/14https://jkms.org https://doi.org/10.3346/jkms.2021.36.e291
Non-alcoholic Fatty Liver Disease and COVID-19
than 0.05 was considered statistically significant. Statistical analyses were performed in SAS 
(version 9.4; SAS Institute Inc., Cary, NC, USA) and R software version 3.6.1 (R Foundation, 
Vienna, Austria).
Ethics statement
This study was approved by the Institutional Review Board of Sejong University (SJU-
HR-E-2020-003). The requirement for written consent was waived by the ethics committee 
due to urgent medical needs during the COVID-19 pandemic.
RESULTS
Descriptive overview
Baseline characteristics of subjects are summarized in Table 1. Among 74,244 adults (age 
groups: 34.4% [20–39 years], 36.6% [40–59 years], and 29.0% [≥ 60 years], 36,060 were 
male [48.5%], and 26,041 (35.1%), 19,945 (26.9%), and 8,927 (12.0%) subjects had HSI-
NAFLD, FLI-NAFLD, and claims-based NAFLD, respectively (Table 1 and Fig. 1). During the 
observation period (Fig. 2), 2,251 (3.0%) tested positive for SARS-CoV-2, 438 (0.6%) had 
severe COVID-19 illness, and 45 (0.06%) suffered COVID-19-related deaths.
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 Excluded, n = 138,524
• 136,373 subjects who did not receive general health examination between 2018 and 2020
• 1,818 subjects with another atiology of liver disease
• 638 subjects with alcohol abuse/misuse
Eligible subjects aged over 20 years-old who underwent SARS-CoV-2 testing
between January 1, 2020 and May 30, 2020 in South Korea
212,768




























Propensity score matching Propensity score matching Propensity score matching
Fig. 1. Study profile. 
SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2, HSI = hepatic steatosis index, FLI = fatty liver index, 
NAFLD = non-alcoholic fatty liver disease.
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Table 1. Baseline characteristics of subjects who performed the SARS-CoV-2 testing in the Korean nationwide cohort (n = 74,244)
Characteristics Entire cohort HSI-NAFLD FLI-NAFLD Claim-based NAFLD
None (HSI < 36) HIS ≥ 36 None (FLI < 60) FLI ≥ 60 None Claim-based NAFLD
Total 74,244 (100.0) 48,203 (64.9) 26,041 (35.1) 54,299 (73.1) 19,945 (26.9) 65,317 (88.0) 8,927 (12.0)
Age, yr
20–39 25,568 (34.4) 17,712 (36.7) 7,856 (30.2) 22,275 (41.0) 3,293 (16.5) 23,904 (36.6) 1,664 (18.6)
40–59 27,182 (36.6) 18,423 (38.2) 8,759 (33.6) 18,854 (34.7) 8,328 (41.8) 23,756 (36.4) 3,426 (38.4)
≥ 60 21,494 (29.0) 12,068 (25.0) 9,426 (36.2) 13,170 (24.3) 8,324 (41.7) 17,657 (27.0) 3,837 (43.0)
Sex
Male 36,020 (48.5) 27,642 (57.3) 8,378 (32.2) 24,670 (45.4) 11,350 (56.9) 31,253 (47.9) 4,767 (53.4)
Female 38,224 (51.5) 20,561 (42.7) 17,663 (67.8) 29,629 (54.6) 8,595 (43.1) 34,064 (52.2) 4,160 (46.6)
Region of residence
Seoul capital area 33,153 (44.7) 21,634 (44.9) 11,519 (44.2) 24,538 (45.2) 8,615 (43.2) 29,315 (44.9) 3,838 (43.0)
Daegu/Gyeongbuk area 14,513 (19.6) 9,522 (19.8) 4,991 (19.2) 10,589 (19.5) 3,924 (19.7) 12,554 (19.2) 1,959 (21.9)
Other area 26,578 (35.8) 17,047 (35.4) 9,531 (36.6) 19,172 (35.3) 7,406 (37.1) 23,448 (35.9) 3,130 (35.1)
History of tuberculosis 1,533 (2.1) 1,077 (2.2) 456 (1.8) 1,076 (2.0) 457 (2.3) 1,347 (2.1) 186 (2.1)
History of stroke 1,021 (1.4) 568 (1.2) 453 (1.7) 592 (1.1) 429 (2.2) 885 (1.4) 136 (1.5)
History of cardiovascular disease 2,326 (3.1) 1,318 (2.7) 1,008 (3.9) 1,356 (2.5) 970 (4.9) 1,942 (3.0) 384 (4.3)
History of hypertension 14,173 (19.1) 7,442 (15.4) 6,731 (25.9) 8,685 (16.0) 5,488 (27.5) 11,312 (17.3) 2,861 (32.1)
History of dyslipidemia 5,255 (7.1) 3,018 (6.3) 2,237 (8.6) 3,284 (6.1) 1,971 (9.9) 4,029 (6.2) 1,226 (13.7)
Systolic blood pressure, mmHg 121.2 ± 14.8 120.1 ± 14.2 123.2 ± 15.5 120.1 ± 14.5 124.2 ± 14.9 120.7 ± 14.7 124.7 ± 14.9
Diastolic blood pressure, mmHg 74.8 ± 10.0 74.5 ± 9.8 75.5 ± 10.3 74.4 ± 9.9 76.1 ± 10.0 74.6 ± 9.9 76.6 ± 10.1
Fasting blood glucose, mg/dL 99.4 ± 24.7 98.4 ± 23.4 101.3 ± 26.8 98.2 ± 23.6 102.7 ± 27.3 98.5 ± 23.5 106.5 ± 31.4
Glomerular filtration rate, mL/min
≥ 90 39,590 (53.3) 26,470 (54.9) 13,120 (50.4) 30,639 (56.4) 8,951 (44.9) 35,359 (54.1) 4,231 (47.4)
60–89 30,153 (40.6) 19,233 (39.9) 10,920 (41.9) 20,718 (38.2) 9,435 (47.3) 26,265 (40.2) 3,888 (43.5)
≤ 59 4,501 (6.1) 2,500 (5.2) 2,001 (7.7) 2,942 (5.4) 1,559 (7.8) 3,693 (5.7) 808 (9.1)
Household income
Low (0–39 percentile) 20,865 (28.1) 12,679 (26.3) 8,186 (31.4) 14,971 (27.6) 5,894 (29.6) 17,867 (27.4) 2,998 (33.6)
Middle (40–79 percentile) 32,640 (44.0) 21,474 (44.6) 11,166 (42.9) 24,862 (45.8) 7,778 (39.0) 29,201 (44.7) 3,439 (38.5)
High (80–100 percentile) 20,739 (27.9) 14,050 (29.2) 6,689 (25.7) 14,466 (26.6) 6,273 (31.5) 18,249 (27.9) 2,490 (27.9)
Smoking
Never smoker 49,077 (66.1) 29,490 (61.2) 19,587 (75.2) 36,848 (67.9) 12,229 (61.3) 43,599 (66.8) 5,478 (61.4)
Ex-smoker 12,063 (16.3) 8,886 (18.4) 3,177 (12.2) 8,116 (15.0) 3,947 (19.8) 10,283 (15.7) 1,780 (19.9)
Current smoker 13,104 (17.7) 9,827 (20.4) 3,277 (12.6) 93,335 (17.2) 3,769 (18.9) 11,435 (17.5) 1,669 (18.7)
Alcoholic drinks, days per week
< 1 46,984 (63.3) 29,360 (60.9) 17,624 (67.7) 33,706 (62.1) 13,278 (66.6) 41,026 (62.8) 5,958 (66.7)
1–2 19,930 (26.8) 13,906 (28.9) 6,024 (23.1) 15,311 (28.2) 4,619 (23.2) 17,897 (27.4) 2,033 (22.8)
3–4 5,929 (8.0) 3,998 (8.3) 1,931 (7.4) 4,301 (7.9) 1,628 (8.2) 5,203 (8.0) 726 (8.1)
≥ 5 1,401 (1.9) 939 (2.0) 462 (1.8) 981 (1.8) 420 (2.1) 1,191 (1.8) 210 (2.4)
Sufficient aerobic activity 29,281 (39.44) 19,139 (39.7) 10,142 (39.0) 21,543 (39.7) 7,738 (38.8) 25,901 (39.7) 3,380 (37.9)
Use of medication
Medication for hypertension 13,339 (18.0) 6,950 (14.4) 6,389 (24.5) 8,124 (15.0) 5,215 (26.2) 10,591 (16.2) 2,748 (30.8)
Medication for dyslipidemia 4,382 (5.9) 4,382 (5.9) 2,401 (5.0) 2,694 (5.0) 1,688 (8.5) 3,299 (5.1) 1,083 (12.1)
Medication for diabetes mellitus 5,955 (8.0) 2,645 (5.5) 3,310 (12.7) 3,633 (6.7) 2,322 (11.6) 4,494 (6.9) 1,461 (16.4)
Medication for cardiovascular disease 2,126 (8.0) 2,126 (8.0) 1,192 (2.5) 1,234 (2.3) 892 (4.5) 1,780 (2.7) 346 (3.9)
NAFLD-related covariates
History of diabetes mellitus 6,379 (8.6) 2,837 (5.9) 3,542 (13.6) 3,909 (7.2) 2,470 (12.4) 4,827 (7.4) 1,552 (17.4)
Waist circumference, cm 80.7 ± 12.6 79.0 ± 12.1 83.8 ± 13.0 79.9 ± 13.4 82.8 ± 9.8 80.1 ± 12.8 84.7 ± 10.5
Body mass index, kg/m2
< 25 47,863 (64.5) 36,020 (74.7) 11,843 (45.5) 35,782 (65.9) 12,081 (60.6) 43,330 (66.3) 4,533 (50.8)
25–30 21,865 (29.5) 11,631 (24.1) 10,234 (39.3) 15,237 (28.1) 6,628 (33.2) 18,397 (28.2) 3,468 (38.9)
≥ 30 4,516 (6.1) 552 (1.6) 3,964 (15.2) 3,280 (6.0) 1,236 (6.2) 3,590 (5.5) 926 (10.4)
Serum triglyceride, mg/dL 152.3 ± 81.5 154.6 ± 80.8 149.1 ± 83.9 136.2 ± 81.3 157.3 ± 82.7 152.0 ± 79.9 150.9 ± 92.7
Gamma-glutamyl transferase, IU/L 36.0 ± 55.4 33.9 ± 59.5 37.0 ± 52.9 34.2 ± 38.7 40.5 ± 60.2 33.6 ± 50.0 52.6 ± 83.2
ALT, IU/L 25.3 ± 26.4 27.6 ± 28.1 20.8 ± 22.0 24.6 ± 25.8 27.1 ± 27.7 25.2 ± 26.2 44.6 ± 40.0
AST, IU/L 5.7 ± 19.1 25.0 ± 16.3 27.0 ± 23.5 25.0 ± 18.0 27.7 ± 21.7 25.6 ± 18.9 38.3 ± 38.2
Data are shown as mean ± standard deviation or number (%).
SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2, FLI = fatty liver index, HSI = hepatic steatosis index, NAFLD = non-alcoholic fatty liver disease, 
ALT = alanine aminotransferase, AST = aspartate aminotransferase.
HSI-NAFLD cohort
After 1:1 propensity score matching in HSI-NAFLD cohort (17,241 for patients without HSI-
NAFLD vs. 17,241 for those with HSI-NAFLD), there was no distinct imbalance between 
the baseline characteristics (Supplementary Table 1, Fig. 3, and Supplementary Fig. 1; all 
SMDs < 0.09). In the matched cohort, subjects with HSI-NAFLD had a high risk of COVID-19 
infection (3.2% for subjects without HSI-NAFLD vs. 3.6% for those with HSI-NAFLD; aOR, 
1.11; 95% CI, 1.01–1.28) and severe COVID-19 disease progression (0.6% vs. 0.8%; aOR, 1.41; 
95% CI, 1.08–1.83).
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Eligible Korean nationwide cohort
Eligible criteria from:
• Aged over 20 years-old
• At least one SARS-CoV-2 test between January 1 and May 30, 2020
• At least one general health examination between January 1, 2018 and index data
• In South Korea
Cohort entry (individual index data)
Enter cohort at date of SARS-CoV-2 test
Main outcome
• Test positive
• Severe COVID-19 illness
• COVID-19-related death







Fig. 2. Flowchart of the study. 
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Fig. 3. The association between NAFLD and positive SARS-CoV-2 test results, severe COVID-19 illness, and COVID-19-related death in nationwide cohort of South Korea. 
The x-axis indicates a log-scale; horizontal bars denote 95% CIs for each of the results; and blue dots indicate propensity score matched results. Severe 
COVID-19 comprised requirement of oxygen therapy, admission to the intensive care unit, invasive ventilation, or death. The figure was generated from our 
previous research and made further advance.15 
COVID-19 = coronavirus disease 2019, HSI = hepatic steatosis index, FLI = fatty liver index, NAFLD = non-alcoholic fatty liver disease, OR = odds ratio, CI = 
confidence interval, SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.
FLI-NAFLD cohort
Results showed consistent tendency after 1:1 propensity score matching, with 19,725 pairs 
produced. There were no major imbalances of baseline characteristics (Supplementary 
Table 2, Fig. 3, and Supplementary Fig. 2; all SMDs < 0.05). In FLI-NAFLD group, COVID-19 
infection (aOR, 1.14; 95% CI, 1.02–1.27) and progression to severe COVID-19 (aOR, 1.35; 
95% CI, 1.05–1.71) were more commonly observed on patients with FLI-NAFLD than those 
without FLI-NAFLD.
Claim-based NAFLD cohort
After 1:1 propensity score matching as 8,830 pairs without major imbalance (Supplementary 
Table 3, Fig. 3, and Supplementary Fig. 3; all SMDs < 0.07), confirmed COVID-19 infection 
(aOR, 1.23; 95% CI, 1.05–1.46) and severe COVID-19 illness (aOR, 1.39; 95% CI, 1.01–1.92) 
were more commonly observed in NAFLD patients.
Severity-dependent analysis
In the full unmatched cohort after stratifying the subjects with NAFLD according to the 
estimated degree of fibrosis using BARD score (Table 2), subjects in advanced fibrosis group 
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Table 2. Severity-dependent association between risk of the COVID-19-related outcomes and NAFLD by BARD scoring system in the Korean nationwide cohort 
(total n = 74,244)
Event Exposure None NAFLD without advanced fibrosisa NAFLD with advanced fibrosisa
COVID-19 HSI-NAFLD
Event number/total number (%) 1,413/48,203 (2.9) 582/18,512 (3.1) 256/7,529 (3.4)
aORb (95% CI) 1.0 (ref) 1.05 (0.95–1.16) 1.20 (1.06–1.34)
FLI-NAFLD
Event number/total number (%) 1,553/54,299 (2.9) 570/16,515 (3.5) 128/3,430 (3.4)
aORb (95% CI) 1.0 (ref) 1.23 (1.11–1.35) 1.32 (1.11–1.59)
Claims-based NAFLD
Event number/total number (%) 1,925/65,317 (3.0) 253/7,053 (3.6) 73/1,874 (3.9)
aORb (95% CI) 1.0 (ref) 1.14 (1.01–1.34) 1.26 (0.98–1.61)
Severe COVID-19c HSI-NAFLD
Event number/total number (%) 259/48,203 (0.5) 105/18,512 (0.6) 74/7,529 (1.0)
aORb (95% CI) 1.0 (ref) 1.02 (0.81–1.29) 1.79 (1.37–2.30)
FLI-NAFLD
Event number/total number (%) 290/54,299 (0.5) 113/16,515 (0.7) 35/3,430 (1.0)
aORb (95% CI) 1.0 (ref) 1.31 (1.05–1.65) 1.89 (1.33–2.70)
Claims-based NAFLD
Event number/total number (%) 349/65,317 (0.5) 61/7,053 (0.9) 28/1,874 (1.5)
aORb (95% CI) 1.0 (ref) 1.46 (1.02–1.90) 2.60 (1.77–3.89)
COVID-19-related death HSI-NAFLD
Event number/total number (%) 21/48,203 (0.04) 12/18,512 (0.06) 14/7,529 (0.18)
aORb (95% CI) 1.0 (ref) 1.10 (0.58–2.20) 4.42 (2.27–8.61)
FLI-NAFLD
Event number/total number (%) 25/54,299 (0.05) 20/16,515 (0.1) 11/3,430 (0.07)
aORb (95% CI) 1.0 (ref) 2.63 (1.48–4.84) 7.06 (3.49–14.70)
Claims-based NAFLD
Event number/total number (%) 38/65,317 (0.06) 1/7,053 (0.01) 6/1,874 (0.32)
aORb (95% CI) 1.0 (ref) 0.22 (0.02–1.73) 5.12 (2.23–12.95)
Numbers in bold indicate significant differences (P < 0.05).
COVID-19 = coronavirus disease 2019, NAFLD = non-alcoholic fatty liver disease, FLI = fatty liver index, HSI = hepatic steatosis index, aOR = adjusted odds ratio, 
CI = confidence interval.
aWe were categorized as severity of liver fibrosis according to the BARD score (0–1, no advanced fibrosis; 2–4, advanced fibrosis); bAdjusted for age (20–39, 
40–59, and ≥ 60 years); sex; region of residence (Seoul Capital Area, Daegu/Gyeongbuk area, and other areas); past medical history/comorbidities (tuberculosis, 
stroke, cardiovascular disease, hypertension, and dyslipidemia); systolic and diastolic blood pressure (continuous); fasting blood glucose (continuous); 
glomerular filtration rate (≥ 90, 60–89, and ≤ 59 mL/min); household income (low, middle, and high); smoking (never, ex-, and current); alcoholic drinks (< 1, 1–2, 
3–4, ≥ 5 days per week); sufficient aerobic activity; current medication for hypertension, dyslipidemia, diabetes mellitus, and cardiovascular disease; cSevere 
outcomes of COVID-19 comprised requirement of oxygen therapy, admission to the intensive care unit, invasive ventilation, or death.
tended to be more infected with COVID-19 (HSI-NAFLD aOR, 1.20; 95% CI, 1.06–1.34; FLI-
NAFLD aOR, 1.32; 95% CI, 1.11–1.59; and claims-based NAFLD aOR, 1.26; 95% CI, 0.98–1.61) 
compared to those without NAFLD. Severity steadily trended upward. Similar severity-
tendency was observed in experiencing severe COVID-19 and COVID-19 related death. 
Subjects having pre-existing NAFLD with advanced fibrosis had a risk for their COVID-19 
disease to progress severely (HSI-NAFLD aOR, 1.79; 95% CI, 1.37–2.30; FLI-NAFLD aOR, 
1.89; 95% CI, 1.33–2.70; and claims-based NAFLD aOR, 2.60; 95% CI, 1.77–3.89) and a higher 
risk for COVID-19 related death (HSI-NAFLD aOR, 4.42; 95% CI, 2.27–8.61; FLI-NAFLD aOR, 
7.06; 95% CI, 3.49–14.70; and claims-based NAFLD aOR, 5.12; 95% CI, 2.23–12.95).
DISCUSSION
Through a large-scale, population-based, nationwide cohort study, we investigated the 
potential association between the presence of NAFLD and risk of SARS-CoV-2 test positive 
and COVID-19 severity and mortality. We identified that the presence of NAFLD affected the 
increased SARS-CoV-2 infectivity and COVID-19 severity among 74,244 subjects underwent 
SARS-CoV-2 testing in South Korea. Additionally, these results found that the severity-
dependent association between NAFLD severity and aforementioned COVID-19-related 
outcomes become more pronounced as liver fibrosis advances. Regarding the robustness and 
generalization of our results, we performed several sensitivity analyses using the alternative 
definitions, such as FLI-NAFLD, HSI-NAFLD, and claims-based NAFLD, which were 
consistent with our main results.
Since the novel pandemic of COVID-19, many researchers have studied the epidemiologic 
features of COVID-19 (especially severity), focusing on severe liver disease including chronic 
liver disease,6 liver cirrhosis,4 and transplant recipients.5 Although NAFLD is a hepatic 
manifestation of metabolic syndrome and the most common cause of chronic liver disease,22 
there are some available studies with relatively small sample sizes23 for patients with NAFLD 
on the disease course of COVID-19 and still remains unclear: predictive factors24 associated 
with COVID-19 severity in USA (n = 351), China (n = 202), and Israel (n = 71), and non-relevant 
factors in USA (n = 589),23 U.K.(n = 193),25 China (n = 280),26 and Mexico (n = 432).27 Most 
recent data has focused on whether underlying hepatic steatosis has an impact on the clinical 
course of the patients with COVID-19, which may not identify the SARS-CoV-2 infectivity 
of the patients having underlying NAFLD.24 To the best of our knowledge, this the first 
study to investigate the association between the likelihood of testing positive for SARS-
CoV-2 and pre-existing NAFLD, which may indicate that the natural course of SARS-CoV-2 
infection is exacerbated and mediated by systemic and chronic inflammation of pre-existing 
NAFLD. Previous studies that demonstrated the association between pre-existing NAFLD 
and COVID-19 severity had limitations due to the cohort size, non-representative sampling 
(sample number, 70 to 600), and naïve NAFLD definition using only HSI or hepatic steatosis 
measurement using concurrent computed tomography (CT) scan.23-27 In a COVID-19 patient, 
it is difficult to distinguish the concomitant liver injury using a CT scan; therefore, it is 
difficult to evaluate their baseline liver steatosis before SARS-CoV-2 infection. Additionally, 
insufficient response effort as important potential confounders (i.e., smoking status, 
physical activity, and alcohol consumption) and selection bias from retrospective clinic-
based sampling and using non-sophisticated statistical techniques.23-27 Thus, these findings 
were difficult to use in the evaluation of the direct effects of underlying NAFLD and may be 
less generalizable and reliable. For these reasons, there was a demand for large-scale and 
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well-designed research to clarify the implications for pre-existing NAFLD. In our study, we 
founded that pre-existing NAFLD was associated with severe COVID-19 illness and death, 
similar to previous studies24; additionally, pre-existing NAFLD was found to be associated 
with an increased risk of COVID-19 infectivity.
Our results for the increased risk of COVID-19-related death was significant only in the fully 
unmatched cohort. Taking into consideration that the association between COVID-19 severity 
and pre-existing NAFLD was significant, the insignificant relationship between COVID-19-
related death and pre-existing NAFLD was caused by the lack of sample number; there were 
only 45 (0.06%) COVID-19-related deaths.
The precise disease interaction mechanism has not been clearly identified, but it is thought 
to be related to the assumptions as follows: firstly, patients with NAFLD has dysregulated 
innate immunity,3 which may induce the increased release of proinflammatory cytokines 
such as tumor necrosis factor alpha and interleukin-6.28 These upregulations trigger 
cytokine storm, a state that may contribute to severe disease progression of COVID-19.28 
Additionally, several NAFLD-related mechanisms such as sterol regulatory element binding 
protein-2 activation, altered lipid synthesis, and liver X-receptor activation may increase the 
inflammatory immune response, which may lead cytokine storm in SARS-CoV-2 infection.29 
In addition to these immune responses, the polarization of Kupffer cells could alter the 
inflammation, promoting M1 to inflammation-suppressing M2; this results in the virulence 
of SARS-CoV-2, and could therefore induce the uncontrolled viral replication and cellular 
damage of the organs.3
Secondly, NAFLD has increased hepatic expression of critical entry points. SARS-CoV-2 may 
enter the cells through angiotensin-converting enzyme 2 receptors (ACE2), which is mainly 
expressed in cholangiocytes and hepatocytes.30 Upregulation of hepatic ACE2 was observed 
in patients with chronic liver disease; thus, these could affect the SARS-CoV-2 infectivity and 
COVID-19 severity in NAFLD patients.5,30 As severe Middle East respiratory syndrome or 
severe acute respiratory syndrome-1 showed liver injury upon post-mortem biopsies, many 
cases of SARS-CoV-2 showed similar liver injury.3,31 The liver injury, which is a common 
finding in patients with severe COVID-19 illness, is most likely caused by immune-mediated 
systemic inflammation.3 Dysregulated immunity caused by NAFLD could make more the 
patient more susceptible to COVID-19 associated liver injury. Liver damage induced by 
pre-existing NAFLD and SARS-CoV-2 might share the immunologic mechanism and occur 
synergistically. This could be a plausible explanation for why patients with NAFLD are more 
vulnerable to SARS-CoV-2 infection and severe COVID-19 outcomes.
There are several limitations to this study. Firstly, we defined NAFLD based on the 
combination of clinical data, lab data, and ICD code in insurance claims-based data. Our data 
did not include information from imaging modalities (i.e., ultrasonography, CT, shear wave 
elstography) or pathologic data. However, we defined NAFLD using the three classifications 
(HSI, FLI, and ICD-10 code), and each of them showed consistent association with COVID-19. 
Recent data also suggested that they showed high diagnostic performance, with their 
c-statistics being 0.85 for FLI and 0.75 for HSI.32 Adopting three definitions for NAFLD 
reduced the risk for overestimation or underestimation.
Secondly, the progressive form of NAFLD (nonalcoholic steatohepatitis) was not fully 
evaluated, and most of the surrogate serum markers for fibrosis (NAFLD fibrosis score, 
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Fibrosis-4 score, European Liver Fibrosis, or FibroTest) could not be calculated because the 
nationwide data did not include platelet count or apolipoprotein A1. Instead, we calculated the 
BARD score to measure NAFLD fibrosis to overcome this issue.21 Further studies with detailed 
analyses for fibrosis on this group of patients are warranted. Thirdly, although we used the 
national level dataset, this dataset did not include the individual data of viral loads and contact 
tracing; therefore, the SARS-CoV-2 test positive results should be interpreted carefully. Finally, 
our results reflected the initial COVID-19 pandemic in South Korea, and the generalization of 
our results should be taken with a grain of salt since the COVID-19 vaccine is now available.33
The preliminary results of our research have been published previously.15 Previous results 
published crude cohort research in short letter format,15 this study have investigated using 
sophisticated statistical techniques (strict exposure-driven propensity score matching method).
Despite these limitations, the main strengths of our study include the use of a nationwide 
cohort with a representative sample size (n = 74,244 subjects), several NAFLD definitions, 
strict exposure-driven propensity score matching (three matched cohorts), and various 
potential confounding factors from the general health examination records (i.e., physical 
activity, alcohol consumption, smoking status, household income). Our nationwide study 
provides the first evidence of the contribution of pre-existing NAFLD to an increased 
likelihood of SARS-CoV-2 infection and severe COVID-19 outcomes.
In conclusion, through large-scale, population-based, nationwide cohort study, we 
investigated the potential association between the presence of NAFLD and risk of an 
increased likelihood of SARS-CoV-2 infection and severe COVID-19 outcomes. Pre-existing 
NAFLD was found to be associated with an increased risk of SARS-CoV-2 infection and worse 
clinical consequences in South Korea. These associations between positive SARS-CoV-2 tests 
and COVID-19 severity and mortality become more pronounced as liver fibrosis progresses. 
Our study provides an advanced insight of the contribution to pre-existing NAFLD and 
COVID-19 pathogenesis. Our results suggest that physicians should exercise extra care and 
give more attention to COVID-19 patients with pre-existing NAFLD.
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Supplementary Table 1
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were tested for SARS-CoV-2
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Supplementary Table 2
1:1 Propensity-score-matched baseline characteristics and FLI-NAFLD among patients who 
were tested for SARS-CoV-2
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Supplementary Table 3
1:1 Propensity-score-matched baseline characteristics and claims-based NAFLD among 
patients who were tested for SARS-CoV-2
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Supplementary Fig. 1
Density and distribution of propensity scores before and after matching in HSI-NAFLD cohort.
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Supplementary Fig. 2
Density and distribution of propensity scores before and after matching in FLI-NAFLD cohort.
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Supplementary Fig. 3
Density and distribution of propensity scores before and after matching in claims-based 
NAFLD cohort.
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REFERENCES
 1. Lee SW, Yang JM, Moon SY, Yoo IK, Ha EK, Kim SY, et al. Association between mental illness and 
COVID-19 susceptibility and clinical outcomes in South Korea: a nationwide cohort study. Lancet Psychiatry 
2020;7(12):1025-31. 
PUBMED | CROSSREF
 2. Kim MS, Jung SY, Lee SW, Li H, Koyanagi A, Kronbichler A, et al. Hepatobiliary adverse drug reactions 
associated with remdesivir: the WHO international pharmacovigilance study. Clin Gastroenterol Hepatol 
2021;19(9):1970-1972.e3. 
PUBMED | CROSSREF
 3. Saviano A, Wrensch F, Ghany MG, Baumert TF. Liver disease and coronavirus disease 2019: from 
pathogenesis to clinical care. Hepatology 2021;74(2):1088-100. 
PUBMED | CROSSREF
 4. Iavarone M, D'Ambrosio R, Soria A, Triolo M, Pugliese N, Del Poggio P, et al. High rates of 30-day 
mortality in patients with cirrhosis and COVID-19. J Hepatol 2020;73(5):1063-71. 
PUBMED | CROSSREF
 5. Meijnikman AS, Bruin S, Groen AK, Nieuwdorp M, Herrema H. Increased expression of key SARS-CoV-2 
entry points in multiple tissues in individuals with NAFLD. J Hepatol 2021;74(3):748-9. 
PUBMED | CROSSREF
 6. Singh S, Khan A. Clinical characteristics and outcomes of coronavirus disease 2019 among patients 




Non-alcoholic Fatty Liver Disease and COVID-19
 7. Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of 
NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol 
2019;71(4):793-801. 
PUBMED | CROSSREF
 8. Shin YH, Shin JI, Moon SY, Jin HY, Kim SY, Yang JM, et al. Autoimmune inflammatory rheumatic diseases 
and COVID-19 outcomes in South Korea: a nationwide cohort study. Lancet Rheumatol 2021;3(10):e698-706. 
PUBMED | CROSSREF
 9. Lagana SM, Kudose S, Iuga AC, Lee MJ, Fazlollahi L, Remotti HE, et al. Hepatic pathology in patients 
dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data. Mod Pathol 
2020;33(11):2147-55. 
PUBMED | CROSSREF
 10. Lazarus JV, Colombo M, Cortez-Pinto H, Huang TT, Miller V, Ninburg M, et al. NAFLD - sounding the 
alarm on a silent epidemic. Nat Rev Gastroenterol Hepatol 2020;17(7):377-9. 
PUBMED | CROSSREF
 11. Woo A, Lee SW, Koh HY, Kim MA, Han MY, Yon DK. Incidence of cancer after asthma development: 2 
independent population-based cohort studies. J Allergy Clin Immunol 2021;147(1):135-43. 
PUBMED | CROSSREF
 12. Lee SW, Lee J, Moon SY, Jin HY, Yang JM, Ogino S, et al. Physical activity and the risk of SARS-CoV-2 
infection, severe COVID-19 illness and COVID-19 related mortality in South Korea: a nationwide cohort 
study. Br J Sports Med. Forthcoming 2021. DOI: 10.1136/bjsports-2021-104203. 
PUBMED | CROSSREF
 13. Lee SW, Yang JM, Moon SY, Kim N, Ahn YM, Kim JM, et al. Association between mental illness and 
COVID-19 in South Korea: a post-hoc analysis. Lancet Psychiatry 2021;8(4):271-2. 
PUBMED | CROSSREF
 14. Yang JM, Koh HY, Moon SY, Yoo IK, Ha EK, You S, et al. Allergic disorders and susceptibility to and 
severity of COVID-19: a nationwide cohort study. J Allergy Clin Immunol 2020;146(4):790-8. 
PUBMED | CROSSREF
 15. Yoo HW, Shin JI, Yon DK, Lee SW. COVID-19 morbidity and severity in patients with nonalcoholic fatty 
liver disease in South Korea: a nationwide cohort study. Clin Gastroenterol Hepatol. Forthcoming 2021. DOI: 
10.1016/j.cgh.2021.07.031. 
CROSSREF
 16. Lee SW, Ha EK, Yeniova AÖ, Moon SY, Kim SY, Koh HY, et al. Severe clinical outcomes of COVID-19 
associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut 
2021;70(1):76-84. 
PUBMED | CROSSREF
 17. Ha J, Lee SW, Yon DK. Ten-year trends and prevalence of asthma, allergic rhinitis, and atopic dermatitis 
among the Korean population, 2008–2017. Clin Exp Pediatr 2020;63(7):278-83. 
PUBMED | CROSSREF
 18. Lee SW, Kim SY, Moon SY, Yang JM, Ha EK, Jee HM, et al. Estimating COVID-19 infection and severity 
risks in patients with chronic rhinosinusitis: a Korean nationwide cohort study. J Allergy Clin Immunol Pract 
2021;9(6):2262-2271.e2. 
PUBMED | CROSSREF
 19. Boursier J, Shreay S, Fabron C, Torreton E, Fraysse J. Hospitalization costs and risk of mortality in adults 
with nonalcoholic steatohepatitis: analysis of a French national hospital database. EClinicalMedicine 
2020;25:100445. 
PUBMED | CROSSREF
 20. Chen LD, Huang JF, Chen QS, Lin GF, Zeng HX, Lin XF, et al. Validation of fatty liver index and hepatic 
steatosis index for screening of non-alcoholic fatty liver disease in adults with obstructive sleep apnea 
hypopnea syndrome. Chin Med J (Engl) 2019;132(22):2670-6. 
PUBMED | CROSSREF
 21. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple 
NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57(10):1441-7. 
PUBMED | CROSSREF
 22. Lee SW, Yang JM, Yoo IK, Moon SY, Ha EK, Yeniova AÖ, et al. Proton pump inhibitors and the risk of 
severe COVID-19: a post-hoc analysis from the Korean nationwide cohort. Gut 2021;70(10):2013-5. 
PUBMED | CROSSREF
 23. Mushtaq K, Khan MU, Iqbal F, Alsoub DH, Chaudhry HS, Ata F, et al. NAFLD is a predictor of liver 
injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or 
progression - The debate continues. J Hepatol 2021;74(2):482-4. 
PUBMED | CROSSREF
13/14https://jkms.org https://doi.org/10.3346/jkms.2021.36.e291
Non-alcoholic Fatty Liver Disease and COVID-19
 24. Sachdeva S, Khandait H, Kopel J, Aloysius MM, Desai R, Goyal H. NAFLD and COVID-19: a pooled 
analysis. SN Compr Clin Med 2020:1-4. 
PUBMED | CROSSREF
 25. Forlano R, Mullish BH, Mukherjee SK, Nathwani R, Harlow C, Crook P, et al. In-hospital mortality 
is associated with inflammatory response in NAFLD patients admitted for COVID-19. PLoS One 
2020;15(10):e0240400. 
PUBMED | CROSSREF
 26. Huang R, Zhu L, Wang J, Xue L, Liu L, Yan X, et al. Clinical features of COVID-19 patients with non-
alcoholic fatty liver disease. Hepatol Commun 2020;4(12):1758-68. 
PUBMED | CROSSREF
 27. Campos-Murguía A, Román-Calleja BM, Toledo-Coronado IV, González-Regueiro JA, Solís-Ortega AA, 
Kúsulas-Delint D, et al. Liver fibrosis in patients with metabolic associated fatty liver disease is a risk 
factor for adverse outcomes in COVID-19. Dig Liver Dis 2021;53(5):525-33. 
PUBMED | CROSSREF
 28. Targher G, Mantovani A, Byrne CD, Wang XB, Yan HD, Sun QF, et al. Detrimental effects of metabolic 
dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of 
COVID-19. Diabetes Metab 2020;46(6):505-7. 
PUBMED | CROSSREF
 29. Sohrabi Y, Reinecke H, Godfrey R. Altered cholesterol and lipid synthesis mediates hyperinflammation in 
COVID-19. Trends Endocrinol Metab 2021;32(3):132-4. 
PUBMED | CROSSREF
 30. Nardo AD, Schneeweiss-Gleixner M, Bakail M, Dixon ED, Lax SF, Trauner M. Pathophysiological 
mechanisms of liver injury in COVID-19. Liver Int 2021;41(1):20-32. 
PUBMED | CROSSREF
 31. Kukla M, Skonieczna-Żydecka K, Kotfis K, Maciejewska D, Łoniewski I, Lara LF, et al. COVID-19, 
MERS and SARS with concomitant liver injury-systematic review of the existing literature. J Clin Med 
2020;9(5):1420. 
PUBMED | CROSSREF
 32. Foschi FG, Conti F, Domenicali M, Giacomoni P, Borghi A, Bevilacqua V, et al. External validation of 
surrogate indices of fatty liver in the general population: the Bagnacavallo Study. J Clin Med 2021;10(3):520. 
PUBMED | CROSSREF
 33. Gianfrancesco MA, Robinson PC. Changing COVID-19 outcomes in patients with rheumatic disease-are 
we really getting better at this? Lancet Rheumatol 2021;3(2):e88-90. 
PUBMED | CROSSREF
14/14https://jkms.org https://doi.org/10.3346/jkms.2021.36.e291
Non-alcoholic Fatty Liver Disease and COVID-19
